Visualitza per autor "Agarwal, Neeraj"
Ara mostrant els elements 1-5 d 5
-
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Carles Galceran, Joan; Chowdhury, Simon; McGregor, Bradley; Merseburger, Axel; Agarwal, Neeraj; Azad, Arun (Future Medicine, 2022-03) -
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
Gulley, James L.; Borre, Michael; Vogelzang, Nicholas J.; Ng, Siobhan; Parker, Chris C.; Carles Galceran, Joan; Agarwal, Neeraj (American Society of Clinical Oncology, 2019-05-01) -
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Carles Galceran, Joan; Fay, Andre P; Shore, Neal; Agarwal, Neeraj; Azad, Arun; Dunshee, Curtis (Future Science Group, 2022-09) -
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer
Matsubara, Nobuaki; Agarwal, Neeraj; Saad, Fred; Azad, Arun; Mateo, Joaquin; Shore, Neal (Future Medicine, 2023-10-26) -
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Agarwal, Neeraj; Azad, Arun; Shore, Neal; Fay, Andre P; Dunshee, Curtis; Carles, Joan (Future Medicine, 2022-02)